O-Acetylbufotenine

The effects of O-acetylbufotenine in humans have not been assessed or reported. Alexander Shulgin speculated about O-acetylbufotenine in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), but did not personally synthesize or test it. ==Interactions==

Bufotenin has low lipophilicity, limitedly crosses the blood–brain barrier in animals, does not produce psychedelic-like effects in animals except at very high doses or administered directly into the brain, and produces inconsistent and weak psychedelic effects accompanied by pronounced peripheral side effects in humans. The O-acetyl substitution of O-acetylbufotenine is expected to be cleaved quite rapidly in vivo, which may hinder the ability of O-acetylbufotenine to cross the blood–brain barrier and deliver bufotenine into the central nervous system. This might be overcome with other O-acyl bufotenin derivatives. ==Chemistry==

Analogues Analogues of O-acetylbufotenin (5-AcO-DMT) include bufotenin (5-HO-DMT), 4-AcO-DMT (psilacetin), 5-MeO-DMT, 5-EtO-DMT, 5-HO-DET, 5-HO-DPT, 5-HO-DiPT, and α-methylserotonin (5-HO-AMT), among others. In addition, other O-acyl derivatives of bufotenin besides O-acetylbufotenine have been developed and studied. One such analogue, O-pivalylbufotenine, has been assessed and has likewise been shown to produce psychedelic-like effects animals. ==History==

O-Acetylbufotenine was first described in the scientific literature by 1968. It was sold online as an analytical standard by 2023. ==Society and culture==

Legal status Canada O-Acetylbufotenine is not an explicitly nor implicitly controlled substance in Canada as of 2025. United States O-Acetylbufotenine is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. ==See also==